We are live on ! Find out more
PI

Pharmstandard International Portfolio holdings

AUM $29M
1-Year Est. Return 3.25%
This Fund
S&P 500
This Quarter Est. Return
+32.12%
1 Year Est. Return
+3.25%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$34.3M
AUM Growth
+$5.46M
Cap. Flow
+$719K
Cap. Flow %
2.1%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
–
Closed
–
Avg Time Held Equity + Options
2.8 quarters
Top 10 Avg Time Held Equity + Options
2.8 quarters
Top 20 Avg Time Held Equity + Options
2.8 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
2.8 quarters
Top 20 Avg Time Held Equity only
2.8 quarters

Top Buys

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$719K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 97.32%
2 Miscellaneous 2.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.3B
$17.4M 50.6%
982,270
– –
2016 Q4
3 quarters
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$10.3M 30.07%
662,063
– –
2017 Q1
2 quarters
TARA icon
3
Protara Therapeutics
TARA
$163M
$3.34M 9.72%
41,698
+12,564
+43% +$719K
2016 Q4
3 quarters
ARGS
4
DELISTED
Argos Therapeutics, Inc.
ARGS
$2.38M 6.93%
662,114
– –
2016 Q4
3 quarters
ARGS
5
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$919K 2.68%
256,030
– –
2016 Q4
3 quarters

Similar funds

IP
Ironsides Partners Boston, Massachusetts $27.7M AUM 1.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
MC
Marcus Capital Northbrook, Illinois $34.3M AUM 30.44% 1-Year Est. Return
RIA
Rocaton Investment Advisors Norwalk, Connecticut $36.6M AUM 10.31% 1-Year Est. Return
FC
Flaherty & Crumrine Pasadena, California $19.8M AUM 3.53% 1-Year Est. Return
WFC
West Face Capital Toronto, Ontario, Canada $16.6M AUM 18.79% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
DCM
Dearborn Capital Management Chicago, Illinois $41.6M AUM 2.79% 1-Year Est. Return

Pharmstandard International's Q3 2017 Portfolio in Review

As of Q3 2017, Pharmstandard International held 5 positions worth $34.3M, up 19% from $28.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2017: portfolio turnover was 0%. Pharmstandard International opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

  • Pharmstandard International added most to Protara Therapeutics in Q3 2017, an estimated $719K increase.
  • Pharmstandard International's ten largest holdings make up 100% of its $34.3M portfolio in Q3 2017.
  • Pharmstandard International opened 0 new positions and closed 0 in Q3 2017.
  • Pharmstandard International's portfolio value rose 19% quarter-over-quarter to $34.3M.

Based on Pharmstandard International's 13F filing for Q3 2017, filed 3 Nov 2017.